Skip to main content
. Author manuscript; available in PMC: 2015 Jun 26.
Published in final edited form as: Mol Cancer Ther. 2007 May 31;6(6):1701–1708. doi: 10.1158/1535-7163.MCT-07-0121

Figure 5.

Figure 5

Antitumor efficacy of Velcade shown by GFP imaging of 5TGM1-eGFP myeloma – bearing mice. Myeloma-bearing mice were randomized to receive Velcade or vehicle i.p. for 4 wks, after which they were sacrificed and the freshly isolated skeletons imaged as described in Materials and Methods. Fluorescence images of bones of a representative mouse from each group. Top, anteroposterior view; bottom, posteroanterior view. Note the dose-dependent effect of Velcade and the almost complete absence of tumor foci (green fluorescence) in the mice that received the two highest doses of the drug.